TsangBin Zeng - Dongsheng Pharmaceutical Director
Director
Mr. TsangBin Zeng is the Director of Dongsheng Pharmaceutical International Co Ltd since September 28, 2010. Mr. Zeng currently serves as the Chief Executive Officer of SunTen Phototech, Inc., a position which he has occupied since 2009. SunTen is pharmaceutical company focused on the development of novel botanical medicines and functional dietary products. Mr. Zeng is responsible for all of aspects SunTens operations, development and fund raising. From 2002 to 2009, Mr. Zeng was the Senior Director of Experimental Medicine and Clinical Pharmacology at AstraZeneca PLC, a globally integrated biopharmaceutical company . While at AstraZeneca, Mr. Zeng was responsible for providing clinical pharmacokinetic and pharmacodynamic for multiple drug development programs, as well as managing the activities of personnel associated with the conduct of clinical studies and assurance of compliance with various regulatory agencies. From 1998 to 2003, Mr. Zeng served as the President and Founder of MegaMed Pharmaceutical Research Institute, a New Jersey based consulting firm for pharmaceutical companies. Mr. Zeng received a B.S. degree from Taipei Medical Universitys School of Pharmacy in 1980. He then received a M.S. degree from National Taiwan Universitys School of Pharmacy in 1982 since 2010.
Age | 52 |
Tenure | 14 years |
Professional Marks | Ph.D |
Phone | 86 10 8858 0708 |
Dongsheng Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 14.01 % which means that it generated a profit of $14.01 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 34.37 %, meaning that it created $34.37 on every $100 dollars invested by stockholders. Dongsheng Pharmaceutical's management efficiency ratios could be used to measure how well Dongsheng Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
BSE CS | HUTCHMED DRC | 72 | |
Paul Carter | HUTCHMED DRC | 55 | |
Lawrence Levitt | RadNet Inc | 74 | |
Dan Eldar | HUTCHMED DRC | 61 | |
Shu Mok | HUTCHMED DRC | 56 | |
Weiguo Su | HUTCHMED DRC | 58 | |
Christopher Nash | HUTCHMED DRC | 56 | |
Michael Stillabower | Merit Medical Systems | 73 | |
Elizabeth Huebner | Merit Medical Systems | 60 | |
Chig Cheng | HUTCHMED DRC | 47 | |
Ann Millner | Merit Medical Systems | 65 | |
Karen Brenner | SunLink Health Systems | 63 | |
Kanji Bando | NH Foods | N/A | |
Tetsuo Katsurayama | HUTCHMED DRC | 58 | |
Christian Salbaing | HUTCHMED DRC | 64 | |
C Ford | SunLink Health Systems | 79 | |
Koichi Ohyama | NH Foods | N/A | |
Akihiko Hiraoka | HUTCHMED DRC | 58 | |
Tsutomu Mizutani | HUTCHMED DRC | 61 | |
Toshiko Katayama | NH Foods | 63 | |
Tadaaki Ito | NH Foods | 58 |
Management Performance
Return On Equity | 34.37 | |||
Return On Asset | 14.01 |
Dongsheng Pharmaceutical Leadership Team
Elected by the shareholders, the Dongsheng Pharmaceutical's board of directors comprises two types of representatives: Dongsheng Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dongsheng. The board's role is to monitor Dongsheng Pharmaceutical's management team and ensure that shareholders' interests are well served. Dongsheng Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dongsheng Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
TsangBin Zeng, Director | ||
Jie Du, Director | ||
Di Wu, Chief Devel. Officer | ||
Duojia Zhang, VP of Sales | ||
Xiaodong Zhu, Chairman, CEO and Pres |
Dongsheng Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc bb equity is not an easy task. Is Dongsheng Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 34.37 | |||
Return On Asset | 14.01 | |||
Profit Margin | 8.14 % | |||
Operating Margin | 11.70 % | |||
Current Valuation | 10.61 K | |||
Shares Outstanding | 17 M | |||
Price To Earning | 0.12 X | |||
Price To Book | 0.03 X | |||
Price To Sales | 0.01 X | |||
Revenue | 18.22 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dongsheng Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dongsheng Pharmaceutical's short interest history, or implied volatility extrapolated from Dongsheng Pharmaceutical options trading.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices. Note that the Dongsheng Pharmaceutical information on this page should be used as a complementary analysis to other Dongsheng Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Dongsheng OTC BB Equity
If you are still planning to invest in Dongsheng Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dongsheng Pharmaceutical's history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |